Related Experiment Videos
Molecular genetic testing for malignant hyperthermia susceptibility.
Thierry Girard1, Susan Treves, Evgueni Voronkov
1Kantonsspital, University of Basel, 4031 Basel, Switzerland. thierry.girard@unibas.ch
Anesthesiology
|April 29, 2004
Summary
Genetic testing reliably identifies malignant hyperthermia (MH) susceptibility, with a high negative predictive value. However, the in vitro contracture test (IVCT) remains crucial for patient safety, especially with negative genetic results.
Area of Science:
- Anesthesiology
- Medical Genetics
- Pharmacology
Background:
- The in vitro contracture test (IVCT) was the gold standard for diagnosing malignant hyperthermia (MH) susceptibility for over 30 years.
- Molecular genetic testing guidelines have been developed for MH susceptibility diagnosis.
- This study evaluates the applicability, sensitivity, and specificity of genetic testing for MH.
Purpose of the Study:
- To assess the effectiveness of molecular genetic testing in diagnosing MH susceptibility.
- To compare genetic testing with the in vitro contracture test (IVCT).
- To determine the advantages of genetic testing for patients with MH susceptibility.
Main Methods:
- In vitro contracture testing (IVCT) performed according to European MH Group guidelines.
- Mutation analysis using polymerase chain reaction (PCR) amplification of genomic DNA.
- Restriction enzyme digestion for mutation identification.
Main Results:
- Out of 67 initially genetically tested patients, 32 were diagnosed as MH susceptible after identifying familial mutations.
- In 20 patients with negative genetic tests, subsequent IVCTs were negative in all but one.
- Three patients with positive IVCT results were also carriers of their familial MH mutation.
Conclusions:
- Genetic testing offers a noninvasive method to confirm MH susceptibility in families with known mutations, with a 50% detection chance.
- The negative predictive value of genetic testing for MH susceptibility is high (0.95).
- Despite high accuracy, IVCT is still recommended for patient safety following negative genetic test results, adhering to established MH diagnostic guidelines.